Skip to main content
. 2021 Feb 1;14(2):46–49.

TABLE 2.

Clinical efficacy of various treatment alternatives in vitiligo

N MARKED RESPONSE GOOD RESPONSE MODERATE RESPONSE MILD RESPONSE NO RESPONSE
Phototherapy 1,996 954 (47.8%) 373 (18.7%) 327 (16.4%) 330 (16.5%) 12 (0.6%)
Phototherapy with topical therapy 1,083 253 (23.4%) 377 (34.8%) 176 (16.3%) 269 (24.8%) 8 (0.7%)
Mono-phototherapy 913 67 (7.3%) 396 (43.4%) 179 (19.6%) 265 (29.0%) 6 (0.7%)
Topical monotherapy 1,004 88 (8.7%) 417 (41.5%) 245 (24.4%) 250 (24.9%) 4 (0.4%)
Subtypes of phototherapy-treated patients
  Segmental 347 34 (9.8%) 213 (61.4%) 33 (9.5%) 66 (19%) 1 (0.3%)
  Acrofacial 312 15 (4.8%) 245 (78.5%) 21 (6.7%) 28 (9.0%) 3 (1.0%)
  Focal 606 116 (19.1%) 256 (42.4%) 125 (20.6%) 102 (16.8%) 7 (1.2%)
  Vulgaris 731 133 (18.2%) 156 (21.3%) 298 (40.8%) 138 (18.9%) 6 (0.8%)
Therapy
  Psoralen and ultraviolet A 367 124 (33.8%) 112 (30.5%) 62 (16.9%) 67 (18.3%) 2 (0.5%)
  Narrow band ultraviolet B 978 184 (18.8%) 304 (31.1%) 196 (20.0%) 288 (29.4%) 6 (0.6%)
  Excimer 651 65 (10.0%) 440 (67.6%) 69 (10.6%) 75 (11.5%) 2 (0.3%)